Vaxart: BARDA modifies COVID-19 trial award to ~$345M; releases $29M for data analysis

Vaxart, Inc.

Total BARDA funding reduced ~$116M to ~$345M after 50% participant reduction due to partial termination in Aug 2025.
Modification releases ~$29M for trial completion and exploratory safety/efficacy analyses.
Vaxart plans to report 12-month data from 400-participant sentinel cohort in coming weeks; main cohort (5,085) data in H1 2027.
CEO states modification is necessary step to unblinding and reporting first data set.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.